SANA

Also known as: MVD1, nitroalkene salicylate

Status

In trials. Investigational and not approved. One first-in-human Phase 1 study (ACTRN12622001519741) gave single and 15-day oral exposures to 41 treated people; metabolic outcomes were exploratory.

What it is

An oral small molecule — a nitroalkene derivative of salicylic acid — not a peptide. In mice it was reported to raise energy expenditure through a creatine-dependent mitochondrial pathway in fat tissue; that mechanism is preclinical.

What published research measured

Cal et al. 2025 (Nature Metabolism) reported the mouse mechanism and the Phase 1 safety study. Two reversible kidney tubular injury events occurred at the highest single exposure and were judged related. Weight and metabolic readouts in people were exploratory, not efficacy results.

Source

Cal et al. 2025, Nature Metabolism (PMC12373507) · ANZCTR ACTRN12622001519741 Primary source

Sources

Educational use only, never medical advice. No doses.